Researchers find new clue to clinical trial failures of MMP cancer therapies

February 12, 2013 by Lynn Yarris, Lawrence Berkeley National Laboratory
Hidetoshi Mori and Mina Bissell. Credit: Roy Kaltschmidt

Proposed cancer therapeutic drugs based on blocking the catalytic activities of matrix metalloproteinases (MMPs), which profoundly remodel the environment surrounding a breast cell, have performed poorly in clinical trials. In mouse studies of MMP14, an enzyme that is often highly expressed in breast cancer, Berkeley Lab researchers have found a possible clue as to why. If confirmed for other MMPs, the finding could point the way to new strategies for future MMP-based cancer therapies.

Berkeley Lab Distinguished Scientist Mina Bissell led a study of MMP14 in nulliparous mice that shows it does not promote invasive behavior in the mammary gland through its catalytic domain, as has been almost universally believed by the cancer research community. Instead, MMP14 promotes invasion through its transmembrane domain, specifically through the direct association of that domain with the beta 1 subunit of integrin (Itgb1), a signaling molecule involved in mammary gland branching and invasion into the fat pad.  The Bissell lab previously showed that mis-regulation of Itgb1 plays a role in breast cancer.

"The reason anti-MMP drugs failed in clinical trials may be that they were aimed at the catalytic domain of these enzymes, which we all thought was the culprit," Bissell says. "The assumption has been that all MMP functions are in the , but we found that MMP14 promotes cancer through its transmembrane domain by mediating signals from the extracellular matrix (ECM) via cross talk and association with Itgb1."

Since high expression of MMP14 has been strongly linked to poor outcomes, including increased death, for , this membrane-bound enzyme became a prime target for pharmaceutical companies seeking to develop therapies. The idea was to inhibit not only MMP14, but also any of the other from functioning.

"The failure and indeed resulting damage of all anti-MMP drugs in clinical trials indicated that MMPs as a class have useful functions that were also being blocked, leading to bad consequences for patients" Bissell says.

The essential non-proteolytic MMP14 activity that Hidetoshi Mori, a scientist in Bissell's research group lab, and other collaborators identified was the association between the transmembrane/cytoplasmic domain of MMP14 and Itgb1 molecules. The MMP14 was found to be expressed in the mammary epithelial cells of nulliparous mice at the tips of branches, where it binds with Itgb1 to control the intracellular and extracellular signals that enable the cells to navigate and invade the fatty stroma.

"Invasion of the stroma and branching by mammary epithelial cells are required for normal breast development. Silencing the MMP14 prevents epithelial cells from moving into the stroma and reduces Itgb1 levels, which results in less branching," Mori says.

Adds Bissell, "When MMP14 interacts with Itgb1 in a tumor, however, these same processes are subverted, the tumor is able to hijack normal cell pathways and cancer is promoted."

These findings suggest that the non-catalytic activity in MMPs could provide a new target for future clinical strategies.

Explore further: New class of proteins allows breast cancer cells to evade tyrosine kinase inhibitors

Related Stories

New class of proteins allows breast cancer cells to evade tyrosine kinase inhibitors

August 13, 2012
Aberrant regulation of cell growth pathways is required for normal cells to become cancerous, and in many types of cancer, cell growth is driven by a group of enzymes known as receptor tyrosine kinases (RTKs). The RTK epidermal ...

Researchers identify possible new oncogene and future therapy target

September 11, 2012
A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance of breast ...

Scientists find that normal breast cells help kill cancer cells

April 13, 2011
It is well known that the human body has a highly developed immune system to detect and destroy invading pathogens and tumor cells. Now, researchers at the U.S. Department of Energy's Lawrence Berkeley National Laboratory ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.